e-Edition
Obituaries
In Loving Memory
Magazines
Subscribe
Login to Comment
Register
jobs
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Life
Commentary
Contact
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
C4 Therapeutics, Inc. - Common Stock
(NQ:
CCCC
)
6.060
+0.020 (+0.33%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about C4 Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
The Latest Analyst Ratings for C4 Therapeutics
May 30, 2023
Via
Benzinga
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC
May 30, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Looking Into C4 Therapeutics's Return On Capital Employed
May 18, 2023
Via
Benzinga
Expert Ratings for C4 Therapeutics
May 08, 2023
Via
Benzinga
Recap: C4 Therapeutics Q1 Earnings
May 04, 2023
Via
Benzinga
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 04, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Where C4 Therapeutics Stands With Analysts
March 28, 2023
Via
Benzinga
Looking Into C4 Therapeutics's Return On Capital Employed
February 28, 2023
Via
Benzinga
C4 Therapeutics's Return On Capital Employed Overview
November 23, 2022
Via
Benzinga
C4 Therapeutics: Q3 Earnings Insights
November 03, 2022
C4 Therapeutics (NASDAQ:CCCC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
April 19, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 24, 2023
Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023
February 24, 2023
Via
Benzinga
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
February 23, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
February 08, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Ford, Atlassian, Amazon And Other Big Stocks Moving Lower On Friday
February 03, 2023
U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Friday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors
January 30, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 25, 2023
Via
Benzinga
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
January 09, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Why Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday's Mid-Day Session
November 25, 2022
Gainers Peak Bio, Inc. (NYSE: PKBO) shares jumped 49.1% to $7.08.
Via
Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Via
Benzinga
US Stocks Mixed On Black Friday; Dow Rises Over 100 Points
November 25, 2022
U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 100 points on Friday. Equity markets will close early on Black Friday, the day after Thanksgiving.
Via
Benzinga
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
November 25, 2022
Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share.
Via
Benzinga
Credit Suisse, Autodesk And Other Big Losers From Wednesday
November 25, 2022
U.S. stocks closed higher on Wednesday, with the Nasdaq Composite gaining more than 100 points. Here is the list of some big stocks recording losses in the previous session.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
November 24, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
November 04, 2022
Upgrades
Via
Benzinga
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 03, 2022
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
Upgrades
Via
Benzinga
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
September 29, 2022
Phase 1/2 Clinical Trial Will Study CFT1946 in BRAF-V600 Mutant Solid Cancers Including Lung, Colorectal and Melanoma; Trial Initiation Expected by Year End 2022
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
wpDiscuz
Insert
